A CD30(−) Transformed Mycosis Fungoides Case Responding Very Well to Systemic Bexarotene and Methotrexate. (June 2014)

• Record Type: Journal Article
• Authors: Zindanci, Ilkin; Kavala, Mukaddes; Turkoğlu, Zafer; Can, Burce; Ozturk, Erman; Zemheri, Ebru; Akbulak, Ozge; Mansuroglu, Cem; Topaloğlu Demir, Filiz
• Is Part Of: International journal of lower extremity wounds. Volume 13:Number 2(2014:Jun.)
• Page Start: 127
• Page End: 129
• Publication Date: 2014-06
• Subjects: mycosis fungoides (MF) -- CD30(−) transformed MF -- methotraxe and bexarotene therapy -- ulcer; Leg -- Wounds and injuries -- Periodicals; Wounds and injuries -- Prevention -- Periodicals; Leg -- Ulcers -- Periodicals; Wound healing -- Periodicals; 617.584
• DOI: 10.1177/1534734614534978
• Languages: English
• ISSNs: 1534-7346

Abstract

The course of mycosis fungoides (MF) is indolent except when transformation to a large T-cell lymphoma occurs. The diagnosis of transformed MF relies on the presence of more than 25% of large cells on biopsy of an MF lesion. Treatment of transformed MF is a major challenge as these patients have poor outcome. Here, we report a 61-year-old man presenting with tumoral ulcer on the plantar area of the foot who was diagnosed cutaneous CD30(−) large cell transformed MF and treated with systemic methotraxate and bexarotene therapy.